TWST Stock Forecast & Price Target

Twist Bioscience is viewed positively because its silicon-based DNA synthesis platform lowers cost and scales production, addressing a key bottleneck in synthetic biology while supporting both core NGS products and DNA synthesis demand. The company also appears to have durable growth drivers from AI-enabled drug discovery, with AI-related orders expected to reach triple-digits % in FY26 at least ~$50M versus ~$25M in FY25, alongside NGS revenues that are expected to stay a majority of sales in FY26 and return to 20%+ growth by FQ4. Financially, management expects meaningful gross margin expansion toward 75-80% and Adjusted EBITDA breakeven by FQ4, while capacity for more than $1B in revenue gives the business substantial operating leverage and room for upside.

Twist Bioscience is viewed negatively because it trades at a significant premium in a competitive life sciences tools market where incumbents like Danaher, Agilent, and Roche can bundle products and pressure pricing. Investor expectations are elevated after a strong stock move, so any quarterly earnings or guidance miss, weaker demand, or slower milestone progress could compress the valuation multiple, especially if NGS momentum softens or customer concentration creates volatility. The profitability case also depends on sustained gross margin improvement and disciplined spending, but increased investment, market share erosion, or delays in R&D and government funding could weaken operating leverage and push out breakeven.